0 The discussion resulted in the adoption by the CPMP of a revised Position Statement on oral contraceptives containing desogestrel or gestodene (CPMP/ 073/ 97, Rev.2), providing information as to the risk of venous thromboembolism associated with the use of oral contraceptives.